Impressive Clinical Results For Argenx’s Oncology Candidate Seal The Deal for Janssen
Executive Summary
Janssen boosts its oncology pipeline with argenx’s novel anti-CD70 antibody, which has potential in a variety of indications.
| Table |
|---|
Advertisement
Related Content
Deal Watch: Boehringer Teams Up In CNS Disorders Again, This Time With Domain
'Totality Of Data' Make A Case For Luspatercept In Beta-Thalassemia, MDS
More Good News For AML As Pfizer And AbbVie/Roche Drugs Get FDA Okay
First Approval Globally For Gilteritinib, In Japan For AML
Otsuka's Guadecitabine Fails in ASTRAL-1 But AML Studies Continue
Daiichi's Phase III Quizartinib Data Pave Way In Niche AML Market
Topics
- Therapy Areas
- Cancer
- Subjects
- Deals
- Clinical Trials
- Commercial
- Industries
- BioPharmaceutical
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC124267
Ask The Analyst
Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
SC124267
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.